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Neurofi brillary tangles (NFTs) are pathologic hallmarks 
of Alzheimer’s disease (AD) and other neurodegenerative 
diseases called ‘tauopathies’ (Lee et al. 2001). NFTs con-
tain abnormal paired helical fi laments (PHFs), of which 
the primary component is hyperphosphorylated tau pro-
tein (PHF-tau) (Grundke-Iqbal et al. 1986; Buee et al. 
2000; Lee et al. 2001). NFTs are also found in the brain 
of patients with frontotemporal dementia and Parkinson-
ism linked to chromosome 17 (FTDP-17), a neurodegen-
erative disease caused by autosomal dominant mutations 
in the tau gene (Hutton et al. 1998). Because phosphor-
ylation of specifi c sites of the tau gene reduces its affi ni-
ty for microtubules, the phosphorylation of tau is a critical 
modifi cation required for NFT formation (Biernat et al. 
1993; Bramblett et al. 1993) and the induction of self-ag-
gregation (Alonso et al. 1996; Alonso et al. 2001).
A number of protein kinases have been studied in 
investigating the molecular mechanism of tau phos-
phorylation (Planel et al. 2002). Among them, the gly-
cogen synthase kinase 3β (GSK3β) and cyclin-depen-
dent protein kinase CDK5/p25 complexes are well 
characterized. They have been biochemically isolated 
as kinases that can phosphorylate tau proteins at mul-
tiple Ser/Thr residues found in PHF-tau, and their ex-
pressions are up-regulated in the brain of patients with 
AD (Ishiguro et al. 1992; Arioka et al. 1993; Imahori 
and Uchida 1997; Patrick et al. 1999). Over-expression 
of CDK5 activator p25 in mouse and GSK3β in fl y en-
hances tau aggregation in vivo (Jackson et al. 2002; 
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Abstract: Neurofi brillary tangles, which are major pathological hallmarks of Alzheimer’s disease (AD), are composed 
of paired helical fi laments (PHFs) containing hyperphosphorylated tau. Specifi c kinases regulate tau phosphorylation 
and are closely linked to the pathogenesis of AD. We have characterized a human tau-tubulin kinase 1 (TTBK1) gene 
located on chromosome 6p21.1. TTBK1 is a serine/threonine/tyrosine kinase that is conserved among species and 
belongs to the casein kinase 1 superfamily. It is specifi cally expressed in the brain, especially in the cytoplasm of 
cortical and hippocampal neurons. TTBK1 phosphorylates tau proteins in both a Mg2+- and a Mn2+-dependent manner. 
Phosphopeptide mapping and immunoblotting analysis confi rmed a direct tau phosphorylation by TTBK1 at Ser198, 
Ser199, Ser202 and Ser422, which are also phosphorylated in PHFs. TTBK1 also induces tau aggregation in human 
neuronal cells in a dose-dependent manner. We conclude that TTBK1 is a neuron-specifi c dual kinase involved in tau 
phosphorylation at AD-related sites and is also associated with tau aggregation.
Keywords: aggregation, Alzheimer’s disease, molecular cloning, phosphorylation, protein kinase, tau protein.
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CDK, cyclin-dependent protein kinase; CK, casein kinase; Cq, 
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Noble et al. 2003), suggesting that up-regulation of tau 
kinase can either cause or enhance tau aggregation.
In addition to such Ser/Thr residues, recent studies have 
demonstrated that PHF-tau is also phosphorylated at Tyr 
residues (Tyr18, 197 and 394 of 2N/4R tau) in the brain of 
patients with AD (Lee et al. 2004; Bhaskar et al. 2005; Der-
kinderen et al. 2005; Vega et al. 2005) and in animal mod-
els of FTDP-17 (Lee et al. 2004; Bhaskar et al. 2005; Vega 
et al. 2005). These fi ndings suggested that not only Ser/Thr 
phosphorylation but also Tyr phosphorylation of tau pro-
tein is involved in NFT formation. Yet, the way in which 
Tyr phosphorylation of tau protein alters its affi nity for ag-
gregation has not yet been determined. Although the sarco-
ma family of nonreceptor tyrosine kinases (src)-like Tyr ki-
nase family, e.g. Fyn and c-Abl, can phosphorylate Tyr18 
and Tyr394 (Lee et al. 2004; Derkinderen et al. 2005), no 
kinase has been reported to phosphorylate Tyr197. In ad-
dition, the known tau kinases are not specifi c to neurons 
where some cell type-specifi c molecular mechanism should 
exist for the PHF-tau and NFT formation.
Thus, the identifi cation of a neuron-specifi c kinase, 
which is involved in PHF-tau formation, will enhance 
the understanding of the mechanism of NFT formation. 
We have screened genes that are relatively specifi cally 
expressed in human brain and have conserved protein 
kinase domain and identifi ed a neuron-specifi c kinase. 
It has been deposited as tau-tubulin kinase 1 (TTBK1), 
which encodes a Ser/Thr/Tyr protein kinase motif and a 
polyglutamate region. Although the bovine homolog of 
the protein has been characterized as a tau-tubulin ki-
nase (TTK), the published mouse-homolog sequence 
contained an error and was translated in a form trun-
cated immediately after the kinase domain (Tomizawa 
et al. 2001). Thus, there is no characterization of full-
length TTBK1. TTBK1 is highly homologous to TTBK2 
and is among the closest relatives of casein kinase CK1 
in the CK1 kinase group, which consists of the CK1, 
TTBK and VRK families (Manning et al. 2002). CK1δ 
is known to be up-regulated in AD brain and can induce 
tau phosphorylation in vitro (Li et al. 2004), whereas 
full-length TTBK2 has never been investigated. TTBK1 
can directly phosphorylate tau protein in vitro and in in-
tact cells at Ser198, Ser199, Ser202 and Ser422 sites. 
TTBK1 also induces tau aggregation in SH-SY5Y cells.
Materials and methods
5’-RACE of TTBK1 cDNA
To fi nd the 5’ end of the cDNA of the human TTBK1 gene, we em-
ployed a GeneRacer kit (Invitrogen, Carlsbad, CA, USA) with hu-
man cortex poly(A)+ RNA isolated by Trizol reagent (Invitrogen) and 
the protocols supplied by the manufacturer. Reverse transcription was 
performed using a gene-specifi c primer 24289 (5’-TGGCCTCGATG-
GACTCCAAGATCTGCTT-3’). The cDNA product was subjected to 
PCR using a set of PCR primers (GeneRacer 5’Primer and 24289; In-
vitrogen) and Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA, 
USA). The PCR conditions were as follows: 2 min at 94°C, followed 
by 25 cycles of 30 s at 94°C, 30 s at 65°C and 2 min at 72°C, with 
15 min at 72°C and then held at 4°C. The PCR products were subject-
ed to nested PCR using a set of primers (GeneRacer Nested 5’ Primer 
and 24290: 5’-CAAGATCTGCTTGCCCAGCCGCAA-3’) using Pfu 
Turbo. The PCR conditions were the same as described for the fi rst 
PCR. The resultant DNA bands were agarose-purifi ed and cloned into 
pCR4-TOPO vector using the TOPO Cloning kit (Invitrogen). The se-
quenced subcloned PCR fragments (named RACE500) corresponded 
to the open reading frame (ORF) region of the KIAA1855 gene.
To generate full-length TTBK1, the RACE500 fragment from 
the pCR4-TOPO vector was hybridized with an equimolar quantity 
of vector containing KIAA1855 in pBluescript (Kazusa DNA Insti-
tute, Kisarazu, Chiba, Japan), followed by DNA polymerization us-
ing Herculase DNA polymerase (Stratagene) to generate a DNA tem-
plate for the NH2 terminal of TTBK1. The PCR conditions were as 
follows: 5 min at 94°C, followed by 10 cycles of 30 s at 94°C, 30 s 
at 65°C and 5 min at 72°C, followed by 15 min at 72°C and then 
held at 4°C. The fused RACE500/KIAA1855 template was subject-
ed to PCR using a primer set (23266, 5’-GAAGTCCTTGAGCTCC-
GTCTC-3’; 25022, 5’-ACGCGTCGACATATGCAGTGCCTAGC-
GGCCGCCCTT-3’) and Herculase. The PCR conditions were as 
follows: 2 min at 94°C, followed by 30 cycles of 30 s at 94°C, 30 s at 
65°C and 2 min at 72°C), followed by 15 min at 72°C and then held 
at 4°C. The resultant product was subjected to expression vector con-
struction of full-length TTBK1. The entire sequence was confi rmed 
through DNA sequencing using a set of 15 primers.
Bioinformatic analysis
Amino acid sequences were obtained from KinBase (http://kinase.
com/kinbase/), and sequence alignments were obtained with the 
ClustalW program (Thompson et al. 1994). The phylogenetic tree 
was computed with ClustalW by the neighbor joining method with 
Kimura’s correlation (bootstrap scores for 1000 iterations). The tree 
was displayed using a TreeView program (Rogers et al. 1986). The 
PESTfi nd program (http://bioweb.pasteur.fr/seqanal/interfaces/pest-
fi nd-simple.html) was used for the PEST sequence search.
Northern blot
The FirstChoice® human total RNA survey panel (Ambion, Autsin, 
TX, USA) and human total RNA panel IV (BD Biosciences, San Jose, 
CA, USA) were used for the northern blot analysis. The northern blot 
was hybridized with a 32P-labeled cDNA probe derived from the 3’-
non-coding region of TTBK1 cDNA using DNA labeling beads (Amer-
sham Biosciences, Piscataway, NJ, USA) according to the manufactur-
er’s instructions. The membranes were exposed to Phosphoscreen, and 
the images were scanned by Typhoon (Amersham Biosciences).
In situ hybridization
The location of mouse TTBK1 mRNA was determined on cryosections 
(10 μm) of brain from adult C57/BL6 mice. For in vitro transcription, 
the digoxigenin RNA-labeling kit (Roche Molecular Biochemicals, In-
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dianapolis, IN, USA) was used with pBluscript SK(–) vector (Strata-
gene) containing the 291-bp mouse TTBK1 PCR product cloned into 
it’s XhoI-EcoRI sites as the template. Labeled probes, corresponding 
to nucleotides 2400–2690 (counted from the ATG start codon), were 
transcribed in either sense or antisense orientation, using either T7 or 
T3 polymerases, respectively. The pre-hybridized sections were then 
hybrizided with digoxigenin-labeled RNA probes, washed, incubat-
ed with alkaline phosphatase-conjugated anti-DIG Fab fragments 
(Roche) and diluted to 1 : 500 following the manufacturer’s instruc-
tions (Roche). After washing with Tris-buffered saline, pH 9.0, sec-
tions were incubated overnight in substrate solution (nitro-blue tetrazo-
lium/5-bromo-4-chloro-3-indolylphosphate; Roche). The sections were 
then counterstained with Hoechst 33342 (Invitrogen), and mounted 
with Vectashield (Vector Laboratories, Burlingame, CA, USA). Phase-
contrast and fl uorescence microscopy were performed using a micro-
scope (Eclipse TE300; Nikon Instruments, Melville, NY, USA) with 
Plan Apo 2×/0.1, Plan-fl uor ELWD 20×/0.45 and Plan-fl uor ELWD 
60×/0.70 objectives (Nikon) with a DVC-1310 digital camera and C-
view imaging software (DVC Company, Austin, TX, USA).
Cell cultures
SH-SY5Y cells obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA) were cultured in a 1 : 1 mixture of 
Dulbecco’s modifi ed Eagle’s medium (DMEM) and Ham’s F12 sup-
plemented with 10% fetal bovine serum (FBS), 10 U/mL penicillin 
and 10 μg/mL streptomycin (all reagents were purchased from Invit-
rogen). African green monkey kidney cells (COS-7) and human em-
bryonic kidney cells (HEK293 cells) were cultured in DMEM sup-
plemented with 10% FBS. Both types of cell cultures were grown in 
a humidifi ed 5% (v/v) CO2/air environment at 37°C.
Vector construction and transfection
The cDNA encoding the full length of TTBK1 (1321 amino acids) was 
inserted into pcDNA3.1+ (Invitrogen) with synthetic linkers, which 
fused an NH2-terminal infl uenza hemagglutinin protein (HA)-epitope 
tag with a Kozac sequence (Kozak 1986). The full-length human tau 
cDNA (htau40, the longest 2N/4R isoform kindly provided by Dr K. 
Paudel, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, 
QC, Canada) was cloned into pcDNA3.1+. COS-7 cells were transient-
ly transfected using FuGENE 6 (Roche) according to the manufactur-
er’s instructions. Forty-eight hours after transfection, cells were lysed 
in Tris-buffered saline containing Triton X-100 (TBST) buffer (50 mm 
Tris-Cl pH 7.4, 150 mm NaCl, 2 mM EDTA, 10% Glycerol and 1% 
Triton X-100) containing phosphatase and protease inhibitors. Lysates 
were centrifuged at 20 000 g. The supernatants, after the protein con-
centration was determined by a BCA assay kit (Pierce, Rockford, IL, 
USA), were used for immunoblotting and immunoprecipitation.
Recombinant adenovirus
A recombinant adenovirus encoding HA-TTBK1-1321 (Ad-HA-
TTBK1-1321) was constructed using the AdEasy system (He et al. 
1998). HA-TTBK1 was excised from pcDNA3.1 using BamHI and 
XbaI, and was directionally subcloned into the pShuttle-CMV at its 
BglII and XbaI restriction sites. Successful recombinants of pShuttle-
CMV were transformed by electroporation along with the adenoviral 
backbone vector pAdEasy-1 into BJ5183 cells. Viral production, pu-
rifi cation and quantifi cation were performed using HEK293 cells and 
CsCl ultracentrifugation as previously described (He et al. 1998). 
The adenoviral vector encoding full-length human tau (Ad-htau40) 
was a kind gift from Dr A. Takashima (Riken Brain Science Institute, 
Wako-Shi, Saitama, Japan) (Sato et al. 2002). Adenoviral vector ex-
pressing green fl uorescent protein (Ad-GFP) has been described in 
detail elsewhere (Ikezu et al. 2003).
Recombinant protein purifi cation
6×His-tagged TTBK1 kinase domain (amino acids 38–319, TTB-
K1cat) was subcloned into the NdeI-XhoI sites of the pET28a vector 
(BD Biosciences) and transformed to BL21DE3 (BD Biosciences) 
containing pG-Tf2 vector (TaKaRa; Mirus Bio, Madison, WI, USA), 
which expresses TF and GroEL-GroES chaperone proteins. After 3 h 
of incubation with 1 mm isopropyl thiogalactoside (dioxane-free; 
Sigma, St Louis, MO, USA) at 37°C, cells were harvested, sonicat-
ed in lysis buffer (50 mm NaH2PO4, pH 8.0, 300 mm NaCl, 10 mm 
imidazole, 1% Triton X-100, 20 mm 2-mercaptoethanol) containing 
protease inhibitors and centrifuged at 40 000 g for 30 min in order to 
collect supernatant. The recombinant protein was batch-purifi ed from 
the supernatant with Ni-NTA His Bind Resin (BD Biosciences), di-
alyzed against buffer A (20 mm Tris-HCl, pH 8.0 and 10% glycer-
ol), and loaded onto HiTrap Q HP column (equilibrated in buffer A; 
Amersham Biosciences) connected to a fast protein liquid chromato-
graph (ÄKTA FPLC system; Amersham Biosciences). The bound 
protein was eluted with a 0–1.0 m gradient of NaCl. The fraction 
containing eluted protein was concentrated using a centrifugal fi lter 
device (Centricon YM30; Millipore Amicon, Bedford, MA, USA), 
and dialyzed with storage buffer (20 mm Tris-HCl, pH 7.0, 250 mm 
NaCl, 1 mm EGTA, 1 mm EDTA, 10 mm 2-mercaptoethanol, 50% 
glycerol and 0.1% Triton X-100) for kinase assays.
In vitro protein kinase assay
The TTBK1 kinase domain fragment (TTBK1cat, 60 ng) was incu-
bated with 500 ng of htau40 in 20 μL of kinase buffer (20 mm Tris-
HCl, pH 7.5, 100 μm ATP and 5 mm dithiothreitol) supplement-
ed with 1 μCi [γ-32P]ATP (Amersham Biosciences) in the presence 
of 10 mm of either MgCl2 or MnCl2 at 30°C for up to 2 h. All re-
actions were stopped by adding 10 μL of 2× Laemmli sample buf-
fer and boiling for 5 min. Following sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE), gels were stained with 
Coomassie Brilliant Blue R-250 (CBB; FisherBiotech, Fairlawn, NJ, 
USA) and dried for autoradiography. The radioactive bands were cut 
from the gel and the radioactivity was quantifi ed by a liquid scin-
tillation counter (PerkinElmer, Wellesley, MA, USA). The kinetics 
of the phosphorylation were analyzed using the best-fi t program of 
Prism v4 (GraphPad Software, San Diego, CA, USA).
Liquid chromatography/tandem mass spectrometry (LC/MS/MS)
Purifi ed TTBK1cat (120 ng) was incubated with 1 μg of htau40 in 
40 μL of kinase buffer in the presence of either 10 mm MgCl2 or 
10 mm MnCl2 at 30°C overnight. The samples were separated by 
SDS–PAGE and the stained bands were cut out and subjected to 
LC/MS/MS analysis as described previously (Kayser et al. 2004). 
Briefl y, gel pieces were digested by trypsin (Promega, Madison, 
WI, USA) and the digested peptides were extracted in 5% formic 
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acid/50% acetonitrile and separated using C18 reversed phase LC 
column (Dionex, Sunnyvale, CA, USA).
A Q-TOF Ultima tandem mass spectrometer (Waters, Milford, 
MA, USA) with electrospray ionization was used to analyze the elut-
ing peptides. The system was user-controlled employing the MassL-
ynx software v3.5 (Waters) in data-dependant acquisition mode with 
a 1-s survey scan (380–1900 D) followed by up to three, 2.4-s MS/
MS acquisitions (60–1900 D). The instrument was operated at a mass 
resolution of 8000 and was calibrated using the fragment ion masses 
of doubly protonated Glu-fi brinopeptides.
Database searches of the acquired MS/MS spectra were per-
formed using Mascot v1.9.0 (Matrix Science, Manchester, UK). The 
database was restricted to human proteins. The search parameters 
were: no restrictions on either protein molecular weight or pI, enzy-
matic specifi city was set to trypsin and phosphorylation was allowed 
as a variable peptide modifi cation. Only peptides that gave a Mascot 
score greater than 13 (p < 0.05) for phosphorylated forms were con-
sidered as positive identifi cations.
Isolation of sarkosyl-insoluble Tau
Sarkosyl extracts were prepared as described previously (Goedert 
et al. 1992) with slight modifi cations. Briefl y, SH-SY5Y cells, infect-
ed with adenovirus (0.5 multiplicity of infection [MOI] of Ad-htau40 
and 0–10 MOI of either Ad-HA-TTBK1-1321 or Ad-GFP), were ho-
mogenized in sucrose buffer (50 mm Tris-HCl, pH 7.4, 0.8 m NaCl, 
1 mm EGTA and 10% sucrose) containing phosphatase and protease 
inhibitors. The homogenates were centrifuged at 20 000 g for 20 min 
at 4°C. The supernatants were mixed to a fi nal concentration of 1% 
sarkosyl and incubated for 1 h at 37°C with gentle shaking. After ul-
tracentrifugation at 100 000 g for 60 min (TL-100; Beckman Coulter, 
Fullerton, CA, USA), the sarkosyl-insoluble pellets were resuspended 
in 2× Laemmli sample buffer for SDS–PAGE and immunoblotting.
Immunoblot analysis and antibodies
Proteins were separated by SDS–PAGE, transferred to Immobilon-
P membrane (Millipore Amicon), and blocked by blocking buffer 
(SuperBlock with 5% skimmed milk; Pierce). The following an-
tibodies (Abs) were used for immunoblotting: α-HA monoclonal 
Ab (HA mAb, 1 : 10 000; Sigma); α-GFP mAb (1 : 3000; BD Bio-
sciences); α-tau T46 mAb (specifi c to tau 404–441, 1 : 1000; In-
vitrogen); Tau-5 mAb (middle of tau, 1 : 1000; BD Biosciences); 
AT8 (phospho-Ser199, Ser202 and Thr205 specifi c polyclonal Ab, 
pAb, 1 : 500; Innogenetics, Gent, Belgium); CP13 mAb (phospho-
Ser202 specifi c, 1 : 250, a gift from Dr P. Davies, Albert Einstein 
College of Medicine, Bronx, NY, USA); and pSer422 pAb (phos-
pho-Ser422 specifi c, 1 : 1000, a gift from Dr A. Delacourte, Lille, 
France). A TTBK1-specifi c rabbit polyclonal antiserum (7589 pAb) 
was raised against a synthetic peptide, FDWEKAGTDALLST, of 
TTBK1308–321 (Alpha Diagnostic Intl, San Antonio, TX, USA), 
purifi ed with a protein-G sepharose FF column (Amersham Biosci-
ences) and used at 1 : 3000 (0.6 μg/mL).
Immunofl uorescence and confocal laser-scanning microscopy
COS-7 cells (1 × 104/well) were plated on poly-d-Lysine-coated 8-well 
LAB-TEK chamber slides (Nunc, Rochester, NY, USA) and transfect-
ed with pcDNA3.1-HA-TTBK1 using FuGENE 6 (Roche). After 48 h 
the transfected cells were fi xed in 4% paraformaldehyde, and permea-
bilized in 0.1% Triton X-100 in phosphate-buffered saline (PBS). Af-
ter blocking with 10% normal goat serum, the cells were incubated 
with α-HA mAb (1 : 1000; Sigma) and 7589 pAb (1 : 300), followed 
by incubation with either Alexa488- or Alexa594-conjugated second-
ary antibodies (Invitrogen), counterstained with Hoechst 33342 (Invit-
rogen), and mounted with Vectashield (Vector Laboratories) and cover 
glass. Digital images were taken with a Nikon TE300 inverted fl uores-
cence microscope (Nikon) using a Plan-fl uor ELWD 40×/0.60 objec-
tive (Nikon) as previously described (Yamamoto et al. 2005).
A confocal laser-scanning microscopic study was performed us-
ing 4% paraformaldehyde-perfused mouse brain and 4% forma-
lin-fi xed human frontal cortex. Frozen sections (30-μm thick) were 
chemically bleached to reduce autofl uorescence following the meth-
od described by Sun et al. (2002), blocked with 10% normal goat se-
rum containing 1% Triton X-100 in PBS, and incubated with prima-
ry antibodies, α-tubulin-β3 mAb (1 : 1000; Promega) and 7589 pAb 
(1 : 300), followed by incubation with either Alexa488- or Alexa568-
conjugated secondary antibodies, counterstained with TOPRO-3 (In-
vitrogen) for nuclear staining, and mounted on glass slides as pre-
viously described (Yamamoto et al. 2005). The digital images were 
captured with a Zeiss LSM410 and 100×/0.30 (oil objective; Carl 
Zeiss AG, Göttingen, Germany).
Statistical analysis
All data were normally distributed. In case of multiple mean com-
parisons, data were analyzed by analysis of variances (anova), fol-
lowed by the Newman–Keuls multiple comparison tests using statis-
tics software (Prism v4.0; Graphpad Software). In the case of a single 
mean comparison, data were analyzed by Student’s t-test. Values of p 
less than 0.05 were regarded as signifi cant.
Results
Structure of the human TTBK1 gene
We isolated the full-length cDNA by 5’ rapid amplifi cation 
of cDNA ends based on the human KIAA1855 gene. This 
cDNA was identical to the tau-tubulin kinase 1 (TTBK1) 
derived from an automated computational analysis ‘kin-
ome’ project (Manning et al. 2002). TTBK1 is located on 
human chromosome 6p21.1 and is composed of 14 ex-
ons and 15 introns with a cDNA length of 6932 bp. The 
TTBK1 protein is 1321 amino acids in length, has a kinase 
domain, and a unique polyglutamate domain in the middle 
region of the sequence (Fig. 1a). Human TTBK1 homologs 
were found in mice, Caenorhabditis elegans and Drosophi-
la melanogaster, the shorter non-catalytic regions of which 
are non-homologous to human TTBK1 (Fig. 1a).
Phylogenetic tree analysis among the CK1 group, 
which consists of CK1, TTBK and VRK families, 
showed that TTBK1 is highly homologous to TTBK2 
(Fig. 1b). Among the CK1 group, CK1δ can phosphory-
late tau in vitro and in cultured cells (Li et al. 2004). The 
alignment of the kinase domain of TTBK1 and CK1δ 
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showed a modest identity of 38% (52% homology, 
Fig. 1c). These results suggest that TTBK1 is the closest 
relative of CK1, but not a member of CK1 family.
Characterization of TTBK1 mRNA and protein ex-
pression
To determine the distribution of the TTBK1 gene, northern 
blotting of a multiple human tissue panel was conducted 
using a probe for human TTBK1(Fig. 2a). TTBK1 mRNA 
was detected as a 7.5-kb mRNA band in adult brain cor-
tex and cerebellum (lanes 1 and 2) and fetal brain tissue 
(lane 23, arrow). This is similar to the sequence length of 
human TTBK1, confi rming its brain specifi city from the 
fetal stage. In addition, a weak expression of TTBK1 was 
detected in both the spinal cord and testis in an image ob-
tained with longer exposure (data not shown). No signifi -
cant expression was detected in any of the other tissues.
In situ hybridization of mouse brain was performed 
to determine the distribution of TTBK1 gene expression 
in the brain. The cortical layers, the CA1 layers of the 
hippocampus, and the granular layer of cerebellum were 
strongly labeled with the mouse TTBK1 complementa-
ry RNA (cRNA) probe (Figs 2b–f). Signals were also 
observed in the perinuclear and cytoplasmic regions of 
the large cortical pyramidal cells in the temporal cortex 
(Fig. 2b). Signals were also seen in the CA1 pyramidal 
neurons (Figs 2c and d) and cerebellum granular neu-
rons (Figs 2e and f). The control sense probe showed no 
hybridization, and the TTBK1 probe did not cross-react 
with TTBK2 (data not shown). These data suggest the 
expression of the TTBK1 gene is specifi c to neurons.
TTBK1 protein expression in neurons
To detect the expression of TTBK1 protein, we pre-
pared a rabbit polyclonal antibody (7589 pAb) raised 
against a synthetic peptide corresponding to the resi-
dues 308–321 of TTBK1 that are conserved in both 
humans and mice (see Materials and methods). The 
specifi city of 7589 has been confi rmed by both immu-
noblotting and immunocytochemistry (Fig. 3).
Frozen sections of human and mouse cortex were 
probed with antibodies to a neuronal marker, tubulin-
β3 (Figs 4a, d, e, f, i and j in green), and 7589 (Figs 4b, 
d, e, g, I and j in red) for confocal laser-scanning mi-
croscopic imaging. The 7589-immunoreactive cells 
were mainly co-localized with tubulin-β3-positive neu-
rons in human (Figs 4a–d, arrowheads) and mouse cor-
tex (Figs 4e–h, arrowheads), and the immunoreactivi-
ty was diminished by pre-incubation of 7589 with the 
antigen peptide (data not shown). These data indicated 
that TTBK1 is present in neurons.
To determine the actual molecular weight (MW) of 
TTBK1, HA- and myc-tagged full-length TTBK1 (HA-
TTBK1) was expressed in COS-7 cells and detect-
Figure 1.  Multiple sequence alignment with tau-tubulin kinase 1 
(TTBK1) and its orthologues. (a) Alignment of human and mouse 
TTBK1, and Caenorhabditis elegans and Drosophila melanogaster 
TTBK (KinBase ID: 16054, 11247, 11973 and 9447, respectively). 
TTBK1 34–308, dual-kinase domain; 309–732, conserved domain 
A; 733–770, polyglutamate domain; 771–1308, conserved domain B. 
Numbers in the diagrams are the percentage homology and similarity 
in parenthesis to human TTBK1. (b) Phylogenetic tree of the human 
casein kinase (CK) family using clustal W and TreeViewer programs. 
The scale bar represents 0.1 amino acid substitution per site. Boot-
strap values (1000 bootstrap iterations) are indicated. Vaccinia re-
lated kinase 3 (VRK3) was removed because of its low homology to 
other kinases in the CK1 group. (C) The comparison of catalytic do-
mains of TTBK1 and human CK1δ (KinBase ID: 14657).
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Figure 2.  Tissue distribution of TTBK1 
mRNA and its protein expression. 
(a) Northern blot of human multiple tis-
sue total RNA panel for tau-tubulin ki-
nase 1 (TTBK1) mRNA. The arrow points 
to a specifi c TTBK1 mRNA band (7.5 kb) 
in the brain and the cerebellum (upper 
panel). Ethidium bromide staining of 28S 
rRNA (lower panel). (b–f) In situ hybrid-
ization of TTBK1 mRNA. (b) Coronal sec-
tions of adult mouse brain probed with 
mouse TTBK1 antisense complementary 
RNA. Mouse TTBK1 mRNA expression is 
observed in the frontal cortical layers (II–
VI) and CA1 region of the hippocampus. 
CC, corpus callosum. (c) The CA1 region 
of the hippocampus. (d) Magnifi cation 
of the inset in (c); the pyramidal layer of 
CA1. (e) Granular layer of the cerebellum. 
(f) Magnifi cation of the inset in (e). Scale 
bars: (b) 100 μm; (c and e), 200 μm; (d 
and f), 50 μm.
Figure 3. Immunofl uorescent staining of tau-tubulin kinase 1 (TTBK1) 
by 7589 in transfected cells. (a–h) The detection of HA-TTBK1 by 
7589 polyclonal antibodody (pAb) in COS-7 cells by double-immunos-
taining with anti-HA monoclonal antibody (mAb) (a and e, green) and 
7589 pAb (b and f, red). Pre-absorption of 7589 pAb with the synthet-
ic antigen peptide resulted in a reduction of staining (f), demonstrating 
the specifi city of the observed signals. Cell nuclei were counterstained 
with Hoechst 33342 (c and g, blue). (d) and (h) present merged imag-
es. Scale bars in panels (d) and (h) represent 50 μm.
TAU-TUBULIN KINASE 1 IN TAU PHOSPHORYLATION AND AGGREGATION 1579
ed using anti-HA antibody, which labeled two bands 
at 100 kDa and 230 kDa (Fig. 4k, lane 1, arrowhead 
and arrow, respectively). Because the predicted MW of 
TTBK1 is 142.7 kDa, it is possible that the full-length 
TTBK1 migrates to 230 kDa because of the negative 
charge of the polyglutamate sequence and the protein 
modifi cation, and the 100-kDa band is its proteolytic 
fragment resulting from protein processing.
To test this possibility, cells were incubated with chlo-
roquine (Cq), a lysosomal inhibitor. Cq treatment increased 
the quantity of the 230-kDa band with a corresponding re-
duction in the 100-kDa protein in a dose-dependent manner 
(Fig. 4k, lanes 2–4). This suggests that the 100-kDa band is 
a lysosomal degradation product of full-length TTBK1.
To examine the endogenous expression of TTBK1 in 
mouse brain, we used the 7589 pAb for immunoblotting 
(Fig. 4l). The antibody detected a 100-kDa band in mouse 
cortex and HA-TTBK1 expressed in HEK293 cells, but 
not in mock-transfected cells (Mock, Fig. 4l). The MW 
shift is caused presumably by the tagging of TTBK1 with 
Figure 4. Immunofl uorescence and immunoblotting of tau-tubulin ki-
nase 1 (TTBK1). (a–j) Immunofl uorescence of TTBK1 in brain tissues. 
Confocal images of human and mouse cortex double-stained with anti-
tubulin-β3 (a, d, e, f, i and j, green) and 7589 (b, d, e, g, i and j, red). 
The cell nuclei were counterstained with TO-PRO-3 (c, d, e, h, i and j, 
blue). The arrowheads indicate co-localization of tubulin-β3 and 7589 
immunoreactivity in cortical neurons. (d) and (i); merged images of (a–
c) and (f–h), respectively. (e) and (j), a higher magnifi cation of the ar-
eas specifi ed in (d) and (i), respectively. Scale bars: (d) and (i), 25 μm; 
(e) and (j), 10 μm. (k) COS-7 cells expressing either HA-TTBK1-1321 
or Mock vector were treated with different concentrations of chloro-
quine (Cq; 10, 50 and 100 mm) for 24 h and samples were probed 
with anti-HA monoclonal antibody (mAb). Arrow, 230-kDa band; arrow-
head, 100-kDa band. (l) Detection of TTBK1 in mouse cortical extracts 
(150 μg) and COS-7 lysate expressing HA-TTBK1 (positive control) 
using anti-TTBK1 rabbit polyclonal antibody (pAb, 7589). Arrowhead, 
100-kDa band of mouse TTBK1 and HA-TTBK1; *, proteolyzed HA-
TTBK1 bands. (m) Autophosphorylation activity of TTBK1 in vitro. Im-
munoprecipitation of HA-TTBK1 expressed in COS-7 cells 24 h after 
treatment either with or without 50 μm Cq using anti-HA mAb (up-
per panel). Autoradiography of in vitro kinase assay using immuno-
precipitated TTBK1 and [γ-32P]ATP (lower panel). Arrows and arrow-
heads indicate full-length TTBK1 ( 230 kDa) and processed TTBK1 
(100 kDa), respectively
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HA and myc. The absence of a 230-kDa protein in the 
mouse cortex suggests a very small quantity of full-length 
TTBK1 as compared with the 100-kDa fragment.
To verify that the 100- and 230-kDa TTBK1 have 
kinase activity, HA-TTBK1 was expressed in COS-7 
cells treated in either the absence or the presence of Cq 
and immunoprecipitated by anti-HA antibody. The im-
munoprecipitated 230- and 100-kDa fragments under-
went autophosphorylation as determined by the autora-
diogram of incorporated [32P]O4 (Fig. 4m, arrows and 
arrowheads, respectively), confi rming that both TTBK1 
forms exhibit kinase activity.
TTBK1 phosphorylates tau protein in vitro
We investigated whether the kinase catalytic domain of 
recombinant TTBK1 (TTBK1cat) can directly phosphor-
ylate tau protein in vitro. Initial attempts to purify recom-
binant full-length TTBK1 from either Escherichia coli 
or baculovirus-infected sf9 insect cells were unsuccess-
ful because of the insolubility of TTBK1. E. coli-purifi ed 
TTBK1cat and 6×His-tagged human tau protein (htau40) 
migrate at 43 and 70 kDa with purity greater than 90%, 
as shown by the Coomassie Brilliant Blue staining of 
the protein (Fig. 5b, left-hand panel). We tested a panel 
of free metals to phosphorylate 6×His-tagged human tau 
protein by TTBK1cat. Mg2+ and Mn2+, but not K+, Ca2+ 
or Zn2+, conditions activated TTBK1cat (data not shown). 
The timecourse study showed that the incorporation of 32P 
into tau by TTBK1cat is faster in the presence of Mn2+ 
than in the presence of Mg2+ (Fig. 5a, 1.2 and 2.2 mol of 
phosphate transfer/mol of tau in the Mg2+ and Mn2+ con-
ditions, respectively). The specifi c activity of TTBK1cat 
was 0.26 and 0.57 μmol/mg/min in the presence of Mg2+ 
and Mn2+, respectively. The incubation of htau40 with 
TTBK1cat caused a greater reduction in the electrophoret-
ic mobility of htau40 than with htau40 incubated without 
TTBK1cat (Fig. 5b, right-hand panel). These data suggest 
that TTBK1cat directly induced phosphorylation and the 
electrophoretic mobility shift of htau40 in vitro.
Identifi cation of phosphorylated amino acid of tau 
by tandem mass spectrometry
We determined the exact htau40 phosphorylation sites in vi-
tro by phosphopeptide mapping using liquid chromatogra-
phy and tandem mass-spectrometry (LC/MS/MS). The LC/
MS/MS data covered 71% of the recombinant htau40 se-
quence, and the possible phosphorylation sites are listed in 
Table 1. Both Mg2+ and Mg2+ conditions identifi ed htau40 
phosphorylation at Tyr197, Ser198, Ser199, Ser202 and 
Ser422 sites, which have all been reported to be phosphor-
ylated in PHF-tau (Iqbal et al. 1989; Morishima-Kawashi-
ma et al. 1995a,b; Hanger et al. 1998; Vega et al. 2005). 
Ser416 and Thr427 are new sites, and Thr427 phosphory-
lation was observed under both Mg2+ and Mn2+ conditions. 
These results suggest that TTBK1 is a critical enzyme for 
the phosphorylation of PHF-specifi c sites of tau protein.
Figure 5. Tau phosphorylation by tau-tubulin kinase 1 (TTBK1) in vitro. 
(A) Representative kinetics of htau40 phosphorylation. (Upper panels) 
Autoradiography of 32P-incorporated htau40 by the catalytic domain 
of recombinant TTBK1 (TTBK1cat) in the presence of 10 mm MgCl2, 
MnCl2 or no metal from 0 to 120 min. (Graph) Phosphotransfer to 
htau40 in the presence of MnCl2 ( ), MgCl2 (□) or no metal (○). Data 
were fi tted to a hyperbola of GraphPad Prism v4.0. Error bars repre-
sent SD of three samples. (b) (Left-hand panel) Left lane: pre-stained 
molecular marker. Right lane: Coomassie Brilliant Blue R-250 staining 
of purifi ed 6×His-tagged TTBK1cat (43 kDa; see Materials and meth-
ods for the purifi cation procedure) and 6×His-tagged htau40 (70 kDa, 
purchased from Calbiochem). (Right panel) Immunoblotting of total 
htau40 (50 ng) using T46 monoclonal antibody (mAb) after overnight 
incubation either with or without TTBK1cat (50 ng) with 10 mm MnCl2. 
Arrowhead, original molecular weight of htau40.
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TTBK1 induces multiple tau phosphorylation and 
aggregation
To test whether the tau phosphorylation sites identifi ed 
by phosphopeptide mapping are actually phosphorylated 
by full-length TTBK1 in tissue-cultured cells, htau40 and 
full-length HA-TTBK1 were transiently co-expressed in 
COS-7 cells for immunoblotting analysis (Fig. 6a). De-
tection of total tau protein using the tau antibody T46, 
the reactivity of which is phosphorylation independent 
(Kosik et al. 1988), revealed a substantial electropho-
retic mobility shift of tau induced by TTBK1 expres-
sion (Fig. 6a, right-hand upper panel). Co-expression of 
htau40 and TTBK1 resulted in multiple tau phosphory-
lations as detected by specifi c antibodies, AT8 (Ser199, 
Ser202 and Thr205 specifi c), CP13 (Ser202 specifi c) and 
pS422 (Ser422 specifi c). Thus, the htau40 phosphoryla-
tion by TTBK1 at Ser199, Ser202 and Ser422 were con-
fi rmed both in vitro and in intact cell systems. Impor-
tantly, pS422 is a PHF-tau specifi c antibody (Hasegawa 
et al. 1992; Zheng-Fischhofer et al. 1998). We could not 
detect Tyr-phosphorylation of htau40 by using anti-phos-
pho-Tyr antibodies (PY20, 4G10 and rabbit polyclonals, 
data not shown). This could be caused by the presence 
of negatively charged either phospho-Ser198 or phos-
pho-Ser199, which might interfere with the interaction 
of phospho-Tyr197 with anti-phospho-Tyr antibodies.
Because tau phosphorylation is closely related to its 
aggregation, we investigated whether the over-expression 
of TTBK1 induced htau40 aggregation in human neuro-
nal cells (SH-SY5Y, Fig. 5b). Co-infection of SH-SY5Y 
Figure 6. Tau-tubulin kinase 1 (TTBK1)-induced tau phosphorylation 
and aggregation in cultured cells, and its expression in the Alzheimer’s 
disease (AD) brain. (a) Phosphorylation of htau40 by HA-TTBK1 in 
COS-7 cells. (Left-hand panel) HA-TTBK1 bands at 230 and 100 kDa 
are indicated by an arrow and an arrowhead, respectively. (Right-hand 
panels) Detection of total htau40 (T46), its phosphorylation at Ser199, 
Ser202 and Thr205 (AT8), Ser202 (CP13) and Ser422 (pS422). 
(b) Tau aggregation induced by TTBK1 expression in SH-SY5Y human 
neuroblastoma cells. Sucrose supernatant protein samples were run 
on SDS–PAGE and immunoblotted using anti-HA (TTBK1), anti-GFP 
and Tau-5, respectively. Sarkosyl-insoluble (SI) fractions were immu-
noblotted using Tau-5.
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cells with adenovirus expressing wild-type htau40 and 
increasing titer of adenovirus expressing HA-TTBK1 re-
sulted in a reduction of sucrose supernatant htau40 (Sup) 
and the accumulation of a sarkosyl-insoluble fraction of 
htau40 (Sarkosyl insoluble; Fig. 6b). Control co-infection 
with an increasing titer of GFP-expressing adenovirus 
had no effect on tau aggregation. These data demonstrat-
ed that TTBK1 signifi cantly increased the tau insolubili-
ty in human neuronal cells. These data support the idea 
that TTBK1 is involved in tau phosphorylation and ag-
gregation in an intact cell system.
Discussion
TTBK1 is a unique protein because it has dual kinase ac-
tivity on human tau protein and is specifi cally expressed 
in neurons. The tissue and brain specifi city of TTBK1 ex-
pression has been confi rmed by northern blotting, in situ 
hybridization and immunohistochemistry of human and 
mouse brains using specifi c 7589 pAb against TTBK1. 
The expression of HA-tagged full-length TTBK1 was 
mainly cytoplasmic, which is consistent with its endog-
enous, neuron-specifi c expression in human and mouse 
cortex. We have also confi rmed two distinct fragments 
of TTBK1 when expressed in COS-7 cells. The discrep-
ancy in the predicted molecular weight (142 kDa) and 
apparent size (230 kDa) of full-length TTBK1 on SDS–
PAGE could be a result of either multiple phosphoryla-
tions of TTBK1 or the negative charge of the polygluta-
mate domain. Similar abnormal migration was found in 
middle MW neurofi laments (NF-M), which also contain 
a polyglutamate domain and have multiple phosphoryla-
tion sites (Napolitano et al. 1987). This discrepancy re-
quires further analysis either by treating the protein sam-
ple with protein phosphatase or through deleting the 
polyglutamate region of TTBK1 to see if these manipu-
lations alter the electrophoresis of the TTBK1 protein.
TTBK1 appears to undergo a post-translational modifi -
cation by limited lysosomal processing to generate a 100-
kDa fragment, which contains the dual kinase domain and 
non-catalytic region. This is specifi c to lysosomes as Cq, a 
lysosomal inhibitor, blocked endoproteolysis and MG132, 
a potent proteasome inhibitor, had no effect on the accu-
mulation of a full-length TTBK1 (data not shown). In-
terestingly, TTBK1 has seven possible PEST sequences, 
which are defi ned as hydrophilic stretches of amino acids 
either greater than or equal to 12 residues in length, which 
contain at least one Pro, one Glu or Asp, and one Ser or 
Thr (Rechsteiner and Rogers 1996). The PESTfi nd pro-
gram identifi ed amino acids 436–447, 528–541, 553–575, 
626–640, 819–834, 1003–1036 and 1119–1144 as pos-
sible PEST sequences (Rogers et al. 1986). Whether the 
putative PEST sequences of TTBK1 are functional and 
required for the lysosome-mediated degradation will be 
explored in future studies. Currently under investigation 
is whether the polyglutamate region remains in the 100-
kDa form. We have also detected an endogenous 100-kDa 
form of TTBK1 in mouse brains, which is also found in 
SH-SY5Y cells (data not shown).
Fyn and c-Abl have been reported to phosphorylate 
tau protein at Tyr18 and Try394, respectively (Lee et al. 
2004; Derkinderen et al. 2005). TTBK1 is the fi rst kinase 
that can directly phosphorylate Tyr197 in vitro, although 
we could not confi rm it in an intact cell system. Among 
other TTBK1-mediated phosphorylation sites, Ser422 
is of particular interest because it appears to be highly 
specifi c for PHF-tau (Hasegawa et al. 1996; Zheng-Fis-
chhofer et al. 1998), and is critically involved in tau ag-
gregation in SH-SY5Y cells (Pennanen and Gotz 2005).
In addition to phosphorylation, TTBK1 induces 
htau40 aggregation in SH-SY5Y cells. A reduction of 
the sucrose supernatant fraction of htau40 is correlated 
with the accumulation of the sarkosyl-insoluble fraction, 
demonstrating that the majority of htau40 is in the insol-
uble fraction by TTBK1 expression. TTBK1 phosphor-
ylates residues critical for tau aggregation in SH-SY5Y 
cells (Ser202 and Ser422, among others; Pennanen and 
Gotz 2005), demonstrating that TTBK1 activation en-
hances tau aggregation through its phosphorylation.
In summary, TTBK1 is a brain-specifi c protein ki-
nase, specifi cally expressed in neuronal cells, phos-
phorylates tau protein at multiple PHF-tau-related res-
idues in vitro and in intact cell systems, and induces 
tau aggregation. TTBK1 may play an important role 
in neural tau phosphorylation and aggregation. Further 
studies are necessary to elucidate the molecular mecha-
nism of TTBK1 expression, processing, activation and 
intracellular signaling in neurons.
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